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Abstract
Background: High-throughput (omic) data have become more widespread in both quantity and frequency of use,
thanks to technological advances, lower costs and higher precision. Consequently, computational scientists are
confronted by two parallel challenges: on one side, the design of eﬃcient methods to interpret each of these data in
their own right (gene expression signatures, protein markers, etc.) and, on the other side, realization of a novel,
pressing request from the biological ﬁeld to design methodologies that allow for these data to be interpreted as a
whole, i.e. not only as the union of relevant molecules in each of these layers, but as a complex molecular signature
containing proteins, mRNAs and miRNAs, all of which must be directly associated in the results of analyses that are
able to capture inter-layers connections and complexity.
Results: We address the latter of these two challenges by testing an integrated approach on a known cancer
benchmark: the NCI-60 cell panel. Here, high-throughput screens for mRNA, miRNA and proteins are jointly analyzed
using factor analysis, combined with linear discriminant analysis, to identify the molecular characteristics of cancer.
Comparisons with separate (non-joint) analyses show that the proposed integrated approach can uncover deeper
and more precise biological information. In particular, the integrated approach gives a more complete picture of the
set of miRNAs identiﬁed and the Wnt pathway, which represents an important surrogate marker of melanoma
progression. We further test the approach on a more challenging patient-dataset, for which we are able to identify
clinically relevant markers.
Conclusions: The integration of multiple layers of omics can bring more information than analysis of single layers
alone. Using and expanding the proposed integrated framework to integrate omic data from other molecular levels
will allow researchers to uncover further systemic information. The application of this approach to a clinically
challenging dataset shows its promising potential.
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Background
Due to the rapid advances in high-throughput technolo-
gies, the quantitative monitoring of various biological
molecules at the genomic scale (transcriptomics, post-
transcriptomics and proteomics, i.e. omics) is now easily
made available to number of laboratories at quickly drop-
ping costs. However, any single omic screen cannot fully
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unravel the complexity of a biological entity: integration
of multiple layers of information, (multi-omic) is therefore
required to understand more of these systems.
This study presents ﬁrst the integrated analysis (tran-
scriptional, post-transcriptional and translational data,
[1,2]) of the multi-panel cancer dataset NCI-60, a set of 60
diverse human cancer cell lines derived from 9 diﬀerent
tissues (http://discover.nci.nih.gov/cellminer/home.do). A
scheme of the process is outlined in Figure 1. Build-
ing on our previous approach to integrate transcriptional
and post-transcriptional data [3], the exemplar goal of
© 2013 Liu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Figure 1 Flowchart of data integration analysis. General outline of data integration, where three steps are involved: (1) mRNA, miRNA and
protein omic data are standardized and merged into one matrix (joint matrix); (2) FA is done on the joint matrix to identify the tissue-speciﬁc factors,
through which key molecules, including mRNAs, miRNAs and proteins, are ﬁltered; (3) Functional analysis is performed using DAVID to extract
cancer-related features.
this analysis is the identiﬁcation of multimolecular fea-
tures able to describe the tissues of origin of each sample.
This dataset is also processed with non-joint approaches
and alternative tools to quantify the information added
by our proposed method. All these analyses and results
are discussed in the body of the article. As a more chal-
lenging and practically relevant case we then tested our
approach on the large multi-molecular ovarian cancer
patients dataset (TGCA dataset, [4]). The results, based
on our proposed approach, are presented in a separate
Section at the end of this manuscript.
For data integration we used Factor Analysis (FA, [5])
applied directly on biological data without any a priori
hypothesis. This is both the potential and the limita-
tion of our approach: FA can isolate molecules that share
patterns of co-variation, meaning that cross layers asso-
ciations among molecules are already elaborated in the
results proposed, as factors contain protein, miRNA and
mRNA. However, this does not resolve the biological
causes behind these associations: reasons of this common
variance have then to be searched manually by an expert
curator. Co-variation may therefore be attributed to the
expression of genes under the same transcription factor,
binding to the proper promoter sites spread across the
genome, or to the repression of a function due to the
silencing of co-expressedmiRNAs, only to name a few.We
made the conscious choice to leave interpretation to man-
ual expert curation to allow maximum ﬂexibility in the
interpretation, spanning from annotations for functions
or pathways to co-localization on the genome. Neverthe-
less, the use of a priori knowledge (namely the tumor
tissue of origin for NCI-60 and clinical classiﬁcations
for TGCA) to constrain via linear discriminant analy-
sis (LDA, [6]) the relation between the latent variables
under study and the factors obtained, eases the process
of results’ interpretation, as it gives a phenotypic support
to the molecular interpretation of the latent structures.
We remark here that alternative approaches to constrain
the factors model are possible and can lead to compara-
ble results. In particular, LDA can be replaced with other
classiﬁers such as Bayesian classiﬁers [7-9], Support Vec-
tor Machine [10], K-nearest-neighbor [11]. More details
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on alternative methods are discussed below and proposed
in the Results and discussion section.
Related work
The earliest attempts of data integration reported in lit-
erature analyze data from individual omics separately and
only downstream of these parallel analyses results are
merged (only to list a few [12-15]). This, although relevant,
implies the loss of important properties which can only
be uncovered when multiple omic dataset are viewed as
a whole. The theoretical background behind this assump-
tion lies in the deﬁnition of emergent property in Systems
Theory, now becoming popular/familiar in Systems Biol-
ogy [16-19]. Emergent properties indicate how some fea-
tures of a system can only become observable when the
system is studied as a whole and not as the sum of its
parts. The justiﬁcation -in a biological context- for the
need to integrate mRNA, miRNA and protein expression
has experimentally been quantiﬁed only recently [20].
More recent approaches have attempted to directly inte-
grate multi-omic data. We cite here iCluster [21] as it
is fundamentally based on the same principles as our
own approach (FA). However, iCluster uses an unsu-
pervised technique to identify the best factors (there
named clusters) that is theminimization of the Proportion
of Deviance (POD). Our approach, conversely, recom-
mends LDA or other classiﬁers which aim at maximizing
the accuracy of factors combinations in predicting some
external categories (tissue of origin, response to ther-
apy) it is therefore a supervised approach. Depending
on the problem under study, supervised or unsupervised
approaches may be necessary. We remark here that the
ability to predict structures in the absence of external
information (i.e. unsupervised) comes at higher computa-
tional costs for iCluster versus our approach (days versus
minutes). PARADIGM [22] is another approach aiming
at the integration of heterogeneous data and, addition-
ally, at the inference of connections among the identiﬁed
molecules. To date this method does not includemiRNAs,
and recovers connections on the bases of the signaling
pathways it has been trained with (therefore excluding
association due, for example, to co-localization on the
genome). Integration of PARADIGM with our approach
(provided they can both be input with the same data)
could bring complementary information on multiomic
analyses.
Finally, for the speciﬁc case of the NCI-60 cancer
cell line dataset, since it has been deeply proﬁled for
many types of research (drug response, chromosomal
aberrations, mutational status, etc.) we highlight, among
the wide range of literature existing, the following 3
researches, as they utilize as objective function for the
evaluation of their results the appropriateness of the pre-
diction of the tissue of origin. In [23] the authors perform
miRNA proﬁling with the purpose of determining tissue-
speciﬁc markers. We used these results as control of the
coherence of our ﬁndings for miRNAs. Blower and co-
workers [24] performed miRNAs screen on the NCI-60
cell lines, and suggest as future work to integrate vari-
ous layers of omics to extract major information, therefore
supporting the type of analysis here proposed. From their
observations the authors conclude that cell line groupings
based on miRNA expression are generally consistent with
tissue type and with cell line clustering based on mRNA
expression, although mRNA expression seems to be more
informative. We will show in our work that indeed -
when integrated- the two layers can bring even more
information. Very recently, other authors [25] proposed
a method to reconstruct association modules containing
cancer aberrations drivers. The method evaluates a large
number of variables including the eﬀects of Copy Num-
ber Variations, genes mutations and methylations on the
expression of mRNA and miRNA as well as the direct-
and anti-correlation among mRNAs and between mRNAs
and miRNAs. Although there are strong and well known
limitations in the consideration of such direct types of
correlations (see [3,24,26]) we think that the integration
of our approach (for the mRNA, miRNA, protein asso-
ciation) with this one (for the DNA layer processing)
could bring additional insight into the characterization of
cancers, and can represent future work in this direction.
Methods
Materials
The NCI-60 is a set of 60 human cancer cell lines
derived from 9 diverse tissues including melanomas
(ME), leukemias (LE), breast (BR), renal kidney (RE),
ovary (OV), nervous central system (CNS), non-small
cell lung (LC), prostate (PR) and colon (CO) canc-
ers (http://discover.nci.nih.gov/cellminer/home.do). Since
1992 these cell lines have been intensively studied and
they have also, more recently, been processed with high-
throughput technologies. The datasets here used are
obtained from two diﬀerent publications, where the same
60 NCI-60 cell lines are considered, prepared according
to the same experimental protocol and sampled. Proﬁles
of mRNA and miRNA can be found in [27] produced
using Agilent technologies, while in [15] mRNA proﬁles
are obtained with Aﬀymetrix HG-U95A and HG-U133A
chips and the protein level is analyzed by reverse-phase
protein lysate arrays (RPLA).
Data preprocessing
The three omic datasets (mRNAs, miRNAs and proteins)
were downloaded from CellMiner (http://discover.nci.
nih.gov/cellminer/home.do). The proprietary Aﬀymetrix
.CEL ﬁles were loaded and processed as described in the
original publications, and ﬁnally mRNA and miRNA were
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treated with quantile normalization [28]. Since mRNA
proﬁles are obtained from diﬀerent labs and platforms,
to account for unexpected variance or noise, we ﬁrst ﬁl-
tered the mRNAs showing diﬀerential behavior between
the 2 datasets (Pearson correlation >0.5). In general, mul-
tiple probes on a chips map on a single gene (Entrez
Gene), therefore, for each gene, we calculated all the Pear-
son statistics between each probe in the two datasets
[15,27]. For each gene, the maximum value was cho-
sen as representative of the correlation of the two genes
between the two studies, obtaining 27808 probes (16734
Entrez Gene IDs). In order to further compact and prop-
erly join the datasets, multiple probes treatment was then
performed to cluster probes from the same gene (hierar-
chical clustering, cutoﬀ height = 0.6). For each cluster
we choose the mean value to represent the expression
of the gene, leading to a 24040 × 60 matrix from the
above 27808 probes. We limited the number of mRNAs
to probes that showed relatively high and diverse expres-
sion across the NCI-60, by calculating, for each mRNA
probe (p) two values: maximum probe intensity, max(p),
and probe inter-quartile range, IQR(p), across the dataset.
In total, 6162 probes (out of 41,000) appeared in both
the top half of max(p) and the top half of IQR(p). Multi-
ple probes processing was also performed on the protein
dataset and a 157 × 60 matrix (94 Entrez Gene IDs) was
ﬁnally obtained. All the 365 miRNAs from [27] were used
without any additional ﬁltering. As a last step, the pre-
processed datasets of mRNA, miRNA and protein were
standardized across all samples using the mean as base-
line: x = (xexp−c)/c, where xexp represents the expression
level and c the mean on all the samples of the same
molecule. The three omic datasets were ﬁnally joined in a
single (6162 + 157 + 365) × 60 matrix on which FA was
performed.
Models deﬁnition
FA is a statistical method used to uncover the structure
underlying a relatively large set of variables, which can be
described as X = FL+ e, where X is the omic joint matrix
with samples representing the variables, F is the factors’
scores matrix representing the latent structure of X, L is
the factors’ loadings matrix which shows the relationships
between factors and variables, and e is the unique factors
matrix. The maximum number(n) of meaningful latent
features (factors) can be computed based on the general
rationale that -upon factorization- the components of a
matrix that explain less variance than the original stan-
dardized variables should be discarded, as they do not
carry relevant information. Since the number obtained
represents a maximum, after which factors may loose
meaning and interpretability, it is useful to compute FA
for all possible number of factors between 1 and n. Each of
these FA results is named a model (M i, i=1,..n) here, and
labeled with the corresponding number of factors (M1,
Mn), each Model is therefore characterized by a growing
number of factors named Fj, j = 1 . . . i.
Factors selection
Models were then selected based on their ability to dis-
tinguish cancers according to any of the relevant prop-
erties available (in our case tissue of origin for NCI-60,
or response to thserapy for TGCA) using LDA. The
χ2-test was used to estimate the signiﬁcance of the
LDA accuracy. The signiﬁcant factors consist of lists
of relevant molecules, weighted by their factors’ scores
(threshold set to 2.6). The key point here is that these
factors directly contain proteins, mRNAs and miRNAs
that do not need further processing to be associated.
These molecules’ groups are then annotated to ease the
interpretation of the properties emerging from this joint
analysis.
Functional analysis
For each cancer subtype, the identiﬁed key mRNAs and
proteins are annotated directly using DAVID, i.e. Gene
Ontology (GO, [29]) PANTHER [30], BIOCARTA [31],
KEGG [32] and RACTOME [33]. To examine the signif-
icance of the enrichment, a modiﬁed Fisher exact test
(EASE score, [34]) was used to calculate the p-value, and
FDR was further adopted to correct for multiple hypoth-
esis testing (threshold 0.05), having the human genome as
background. The miRNAs were annotated based on their
targets identiﬁed via TargetScan [35].
Comparison with other approaches
We compared our FA-based approach with othermethods
in two ways: i) joint analysis versus separate analysis and
ii) FA-based joint approach versus other joint method.
In the ﬁrst comparison, the separate analysis treated the
mRNA, miRNA and protein datasets as separate matri-
ces and imputed them separately in the pipeline FA+LDA,
this outputs, for each omic layer a combination of tissue-
speciﬁc factors. The key molecules in each omic layer are
merged tissue-wise for functional annotation as described
in Functional Analysis.
The second comparison tests the results on a diﬀerent
way of integrating the 3 omic layers using other classical
methodologies, i.e. the combination of hierarchical clus-
tering (HC) and SAM [36]. The joint (6162+157+320)×
60 matrix is used as input to HC via the function hclust
in the R package stats, which results in diﬀerent clus-
ters (groups) speciﬁc to diﬀerent tissues of origin. SAM
is then used to group the clusters and to identify the
key molecules (from 3 omic layers). Functional analysis is
done similarly to the FA-based integratedmethod. Further
description about the comparisons is discussed in Results
and discussion section
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Results and discussion
For our dataset, the maximum number of meaningful fac-
tors is n=16. In the present manuscript we chose to focus
on cancers tissue types, since they represent an easy-to-
validate feature for which novel information can be rapidly
integrated (see also Related work Section). LDA identi-
ﬁes as the best model to discriminate the samples with
respect to the tissue of origin the 8-factor model (M8)
which can signiﬁcantly discriminate the tissue of origins
with accuracy (0.833). In particular, F1, F2, F3, F4, F5, F7
and F8 of this model can be used to discriminate respec-
tively ME, CO, LE, RE, OV, LC and CNS cancers from
other tissues of origin with signiﬁcantly high accuracy
(>0.9, see Table 1 for details). For the separate analysis,
the best models to discriminate the tissue of origin are
M8 (among M1-M14) for mRNA (accuracy 0.783), M10
(among M1-M20) for proteins (accuracy 0.833) and M9
(amongM1-M16) for miRNA (accuracy 0.633), details on
the factors can also be found in Table 1.
In the rest of this section we report the biological mean-
ing of the factor which loadings show the clearest relation
with the tissue of origin in the integrated analysis, that is
F 1 for melanomas (full molecules list in Additional ﬁle
1). In particular, we highlight how the method is able to
identify two relevant types of information: a complete and
up-to-date set of miRNAs -which involvement in tumor-
ous processes is being increasingly appreciated-, and the
crucial players in the Wnt pathway which importance in
Melanomas is discussed in light of the most recent ﬁnd-
ings. Finally, a comparison with the results obtained with
other approaches is also reported.
Before entering these details, we can generally observe
an interesting ﬂow of information, changing with the dif-
ferent type of data being integrated and thus annotated
in the analysis. In particular, we can observe that the
joint analysis (Table 2, columns 2-4) gives fully relevant
molecular information only when all 3 types of molecules
are being annotated. In fact, although pigmentation dur-
ing development, pigmentation, melanocyte diﬀerentia-
tion, pigment cell diﬀerentiation and melanin metabolic
process are constantly statistically signiﬁcant, Melanogen-
esis and melanin metabolic process only appear when
proteins or proteins and miRNAs are included for anno-
tation. Compared to the separate analysis -although both
methods give complete molecular information on biologi-
cal processes related to pigmentation during development,
pigmentation, melanocyte diﬀereniation and pigment cell
diﬀerentiation- the joint analysis enriches the descrip-
tion of Melanogenesis, that is the major process upstream
the melanocyte diﬀerentiation and pigmentation. Con-
versely, the separate analysis cannot report as enriched the
melanin biosynthetic process and melanin metabolic pro-
cess, which are processes related to the basal melanocyte
physiology (see Table 2, columns 5-7).
Relevance of miRNAs in Melanoma The miRNA list
identiﬁed by the proposed integrated method are shown
in the worksheet Joint in Additional ﬁle 1. Our results
indicate that miR-204 and miR-211 are important in
melanoma cell lines and this is consistent with spe-
ciﬁc tumor proﬁles previously reported [23]. In partic-
ular, miR-211 transcription is described to be regulated
by the microphthalmia-associated transcription factor
(MITF), a master switch of melanocytes development
and melanoma progression via Wnt/β-catenin signaling.
In a deeper investigation [37] an additional mechanism
of action is proposed: MITF transcriptionally induces
miR-211 to inhibit the translation of POU3F2/BRN2
(POU class 3 homebox 2), therefore increasing the inva-
sive potential of tumor cells. Consistently, in our anal-
ysis MITF as well as POU3F2 appear to be relevant in
the melanoma. Sakurai and colleagues [38] found that
Table 1 Models and factors that discriminate the tissue of origins via joint and separate analysis
Methods Joint Separate
Data mRNA & Prot &miRNA mRNA Prot miRNA
Best Model M8 M8 M10 M9
Tissue & Factor
ME F1 (0.98, 3 × 10−13) F1 (0.98, 3 × 10−13) F4 (0.93, 7 × 10−9) F1 (0.98, 3 × 10−13)
CO F2 (0.97, 8 × 10−11) F2 (1, 7 × 9−15) F8 (0.92, 1 × 10−5) F2 (0.95, 2 × 10−9)
LE F3 (1.0, 9 × 10−15) F3 (1, 9 × 10−15) F1 (0.98, 1 × 10−12) F3 (1.0, 9 × 10−15)
RE F4 (0.98, 7 × 10−13) F4 (0.97, 7 × 10−13) F10 (0.93, 1 × 10−7) F7 (0.93, 3 × 10−7)
OV F5 (0.9, 2 × 10−3) F5 (0.92, 1 × 10−5) F3 (0.9, 3 × 10−3) F9 (0.92, 8 × 10−5)
LC F7 (0.95, 8 × 10−10) F7 (0.92, 8 × 10−7) F2 (0.93, 3 × 10−8) NA
CNS F8 (0.97, 5 × 10−10) F8 (0.93, 2 × 10−5) F7 (0.95, 5 × 10−8) F8 (0.95, 1 × 10−3)
The ﬁrst 3 rows in the table describe a hierarchy of information about the factor analyzed to extract information relevant for the tissue of origins listed in column 1.
Namely: the type of analysis, that is joint or separate. Within the separate analysis 3 options are possible i.e. analysis of mRNA only, or miRNA only or proteins only.
Finally, the factor analysis model (M) chosen to describe the tissue is noted in row 3, the number indicates the number of factors obtained from the analysis. Finally
each cell in the matrix indicate which factor among the ones available in the model better describe each tissue type. In each cell, accuracy (acc.) and p-value related to
the ability of the Factor to predict the tissue are reported.
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Table 2 Comparison of the functional annotation results from diﬀerent methods for Melanoma
Molecules
Joint Analysis FA (HC) Separate Analysis FA (HC)
mRNA mRNA mRNA mRNA mRNA mRNA
&Prot &Prot +Prot +Prot
Biological terms &miRNA +miRNA
GO:0048066 pigmentation during development X (X) X (X) X (X) X (X) X (X) X (X)
GO:0043473 pigmentation X (X) X (X) X (X) X (X) X (X) X (X)
GO:0030318 melanocyte diﬀerentiation X (X) X (X) X (X) X (X) X (X) X (X)
GO:0050931 pigment cell diﬀerentiation X (X) X (X) X (X) X (X) X (X) X (X)
GO:0042438 melanin biosynthetic process X ( X) X (X) X (X) - (X) - (-) - (-)
GO:0006582 melanin metabolic process - (-) X (X) X (-) - (-) - ( -) - (-)
GO:0046148 pigment biosynthetic process - (-) - (X) - (-) - (-) - (-) - (-)
hsa04916:Melanogenesis - ( -) X (-) X (-) - (-) - (-) - (-)
BP00193:Developmental processes - (-) X (-) - (-) - (-) X (X) - (-)
GO:0010033 response to organic substance - (-) X (-) - (-) - (-) - (-) - (-)
GO:0019233 sensory perception of pain - (-) X (-) - (-) - (-) - (-) - (-)
GO:0030029 actin ﬁlament-based process - (X) - (X) - (-) - ( -) - (-) - (-)
GO:0030036 actin cytoskeleton organization - (X) - (X) - (-) - (-) - (-) - (-)
GO:0001501 skeletal system development - (-) - (-) - (-) - (-) X (X) - (-)
Comparison of the annotations done on the joint versus the separate analysis for the FA based method (indicated with FA). The table also contains the comparison
with the alternative method hierarchical clustering and SAM (indicated by HC, the results are listed in parentheses in each cell and refer to the application of HC to the
joint or separate analysis coherently with the FA annotation in the same cell). & indicate that the annotations are done on the corresponding molecules treated jointly
and + indicates that annotation is done downstream of 3 independent analyses.
miR-211 participates to the expression of Preferentially
Expressed Antigen of Melanoma (PRAME, c23). In our
case, PRAME is identiﬁed as key gene and the functional
analysis results show that it may work in the apoptosis/cell
death and proliferation processes.Moreover, in our results
cell death and apoptosis emerge as related to the pres-
ence of miR-363 and miR-146a. High levels of miR-146a
were in fact revealed in the melanoma cell lines, and their
function is known to be related to their metastatic poten-
tial [23]. Finally, we identiﬁed a set of miRNAs in the
miR-509-miR-514 cluster, including miR-509-3-5p, miR-
509-3p, miR-509-5p, miR-513c and miR-514. Comparing
to other tissues, all these miRNAs showed a high level of
expression in melanomas, consistent with literature ﬁnd-
ings [23,39]. This miRNA cluster is located on Xq27.3 in
the human genome, very close to the Melanoma Anti-
gen family A genes (MAGEA1, MAGEA4 and MAGEA8)
and CSAG2 (CSAG family, member 2), which are key
mRNAs and expressed at a high level in our data. There-
fore, this miRNA cluster, along with melanoma associated
antigens, is likely to be cis-transcribed and may represent
a molecular signature able to distinguish melanoma from
all other tumor tissues. The separate analysis highlighted
two more miRNAs: miR-224 and miR-502-3p, which are
melanoma-relevant. However, no connections between
mRNAs/proteins and miRNAs were found.
Emergence of theWnt Pathway in Melanoma We then
turned our attention to the genes known in literature to be
related to melanoma. In particular, human pigmentation
appears to be one of the main modulators of individuals’
risk of developing malignant melanoma [40]. Among the
relevant genes we identiﬁed, Dopachrome Tautomerase
(DCT) is reported to play a critical role in lowering the
oxidative stress melanocytes are physiologically subjected
to during pigmentation; it is also known that levels of DCT
are elevated in melanoma cell lines which are particularly
resistant to chemotherapy and radiation [41]. Edn Recep-
tor Type B (EDNRB) is another relevant gene essential
for the development of melanocytes and has been associ-
ated with melanoma progression [42]. Finally, Tyrosinase
(TYR) and Tyrosinase Related Protein 1 (TYRP1/gp75),
two proteins involved in the melanocyte pigmentary
machinery, are increasingly used as diﬀerentiation mark-
ers given their emerging role in malignant transformation
and tumor progression [43]. In our results, these genes
all contribute to the emergence of the Melanogenesis
annotation, the physiological process driving diﬀerenti-
ation of neural crest progenitors, their migration and
maturation into functional melanocytes. Consequently,
we chose to investigate the connection among all the
genes related to this annotation, making use of STRING
(http://string.embl.de/, [44]). This database of known and
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predicted protein interactions, includes direct (physical)
and indirect (functional) associations derived from four
sources: genomic context, high-throughput experiments,
coexpression and literature. The 4 sources can be further
extended into 8 types of evidences and in a STRING map,
edges’ color represent the diﬀerent types of evidence. The
conﬁdence score (set here to the default valuemedium) is
an indicator of the robustness of the connection.
As it is shown in Figure 2, the mild increase in the num-
ber of molecules between the joint and separate analysis
(11 in Figure 2(a) versus 6 in Figure 2(b)) is nonethe-
less able to drastically change the informative content
of the ﬁndings. Genes CTNNB1 and GSK3B emerging
in the joint analysis are of particular relevance. These
tightly interacting molecules related to the Wnt canonical
pathway, are known to crucially regulate melanoblasts fate
[45] and even to be involved in melanoma [46]. CTNNB1
and GSK3B genes codify for protein β-catenin and its
repressor, Glycogen Synthase Kinase 3-β , respectively.
Notably the former is the key factor of the highly con-
served canonical Wnt signaling pathway, which activation
culminates in the β-catenin cytosolic accumulation and
nuclear translocation. Then its interaction with transcrip-
tion factors results in the regulation of target genes medi-
ating cell fate, proliferation, and migration. Mutations or
aberrant expression of canonical Wnt pathway compo-
nents, have been identiﬁed to promote deregulation of
β-catenin-responsive genes aﬀecting cell diﬀerentiation
and apoptosis, and are thus responsible of tumor initiation
and progression. In particular in colon and liver cancers
Figure 2Melanogenesis. Network of interaction among the molecules related to Melanogenes using STRING (http://string.embl.de/) obtained
from diﬀerent methods, including joint and separate analysis based on FA+LDA (combination of factor analysis and linear discriminant analysis) and
HC+SAM (combination of hierarchical clustering and SAM). (a) Joint approach (FA+LDA) and (b)Separate approach (FA+LDA) are from the
joint and separate analyses based on FA+LDA methods, respectively. The loss of connectivity due to the lack of molecules CTNNB1 and GSK3B in the
separate analysis corresponds to a loss of information related to the Wnt signaling pathway which is of utmost relevance in melanocyte
diﬀerentiation and melanoma onset. (c) Joint approach (HC+SAM) and (d) Separate approach (HC+SAM) illustrate the results from the joint
and separate analyses based on HC+SAMmethods, respectively. Similarly to the FA+LDA methods, joint analysis shows better performance than
the separate analysis since the latter is not able to identify the key factor TYR for melanogenesis. Overall, regarding melanogenesis, FA+LDA
methods outperforms HC+SAM, and the joint analysis is more informative than the separate analysis. Joint analysis based on FA+LDA only is able to
uncover the emergent melanogenesis process in melanoma.
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canonical Wnt signaling produces enhanced quantities
of cytoplasmic and nuclear localized β-catenin, which
correlates with invasion and poor prognosis. Conversely
β-catenin in melanoma is associated with good outcome
and improved survival, while its reduced expression is
linked to cancer progression, including metastasis. A wide
range of studies have validated the immunohistochemi-
cal detection of nuclear β-catenin as a survival marker in
several cancers, solidifying the importance of this path-
way in oncogenesis and in tumor progression [47]. Since
increased nuclear β-catenin is found in the majority of
benign nevi and in tumors with low proliferative index, it
has been considered as a surrogate marker of cell diﬀeren-
tiation and useful to identify the histological phenotype of
tissue lesions [48,49].
What is unique to the joint analysis (see Figure 2(a)),
is that, within Melanogenesis the contribution of the
Wnt/β-catenin signaling pathway emerges. Without gene
CTNNB1 (missing in the separate analysis, Figure 2(b))
it is not possible to mention the canonical Wnt signaling
pathway and therefore, all the above considerations, that
are crucially related to the characterization of melanoma
and carcinogenesis, have to be ignored. In summary
through our computational results we can conclude that
the joint approach is able to obtain more information then
the separate one, from the same data. As a consequence,
our ﬁndings can be informative on the mechanism under-
lying the biology of tumors and therefore contribute to
understanding the nature of the neoplastic lesion, which
is of crucial importance to identify a suitable and eﬀective
therapy.
Comparison with other integrated approaches
Preprocessing, deﬁnition of joint and separate analyses
and the method used to evaluate the signiﬁcance of the
discrimination (χ2-test) are the same used in the FA
based-method. Results on the annotations are listed in
parentheses in Table 2.
Alternative Joint Analysis The hierarchical clustering
results show that the joint analysis can signiﬁcantly dis-
criminate the tissues with global accuracy 0.62 (p-value <
10−7) lower than the FA based method (0.83). The accu-
racy and p-values for discriminating individual tissues
from others are CNS (1, 2 × 10−12), CO (0.93, 1 × 10−11),
LE (0.95, 9.4 × 10−14), ME(0.98, 1 × 10−11), LC(0.93, 1 ×
10−7), RE(0.98, 4 × 10−11). For a detailed and fair com-
parison SAM was used to select the most diﬀeren-
tially expressed molecules, through comparison of the
melanoma cluster with all other tissues. SAM identiﬁed
an heterogeneous signature of 159mRNAs, 2 proteins and
21 miRNAs for melanoma (FDR ≤ 0.001,  = 2.6). Sim-
ilarly to the FA-based joint analysis, mRNAs and proteins
were signiﬁcantly enriched in the biological terms pig-
mentation during development, pigmentation, melanocyte
diﬀerentiation, pigment cell diﬀerentiation and melanin
biosynthetic process. However, the important pathway
melanogenesis did not appear to be signiﬁcantly enriched.
Only ﬁve genes, DCT, EDNRB, MITF, TYR and TYRP1
are found in the melanogenesis pathway, again missing
the essential Wnt signaling pathway genes: CTNNB1 and
GSK3B (see Figure 2(c)). Comparing to the FA joint anal-
ysis, more miRNAs (21 versus 14) were identiﬁed. In
particular, the miR-509-514 cluster is shared with the FA
joint analysis, but no nearby genes, such as MAGEA1,
MAGEA4, MAGEA8 and CSAG2 were identiﬁed in the
list of key mRNAs, nor proteins.
Separate Analysis Using hierarchical clustering, both
mRNAs and miRNAs can perfectly discriminate ME
from other tissues (0.98, 1 × 10−11 ). Conversely, pro-
teins alone are not able to identify ME and therefore we
did not apply SAM to this dataset. On the contrary, on
mRNAs, SAM was able to identify 149 molecules, sig-
niﬁcantly enriched in pigmentation during development,
pigmentation, melanocyte diﬀerentiation and pigment
cell diﬀerentiation. As in the clustering joint analysis,
the melanogenesis pathway information did not emerge
as an enriched one, and only DCT, EDNRB, MITF and
TYRP1 were included, see Figure 2(d). Regarding the miR-
NAs, 20 molecules -most of which are shared by the two
(joint and separate) analyses- are found to characterize
ME, meaning that no additional nor diminished informa-
tion appears when comparing miRNA results to the joint
analysis. Considering the nearby genes of the miR-509-
miR-514, only MAGEA6 (Melanoma Antigen family A 6)
and LOC100130935 (CSAG2) located at Xq28, which are
also highly expressed in ME, are found in the mRNA list.
Application of the TCGA dataset
To asses our approach not only in terms of the
improved knowledge obtained from the joint versus
separate analysis, but also in terms of the relevance
of the information carried by the latent features, we
applied the method to a more complex dataset that
is a large high-grade serous ovarian adenocarcinomas
dataset (HGS-OvCa)[4]. For each patient several clinical
parameters are provided, namely: AgeAtDiagnosis, VITAL
STATUS, TUMORSTAGE , TUMOR GRADE, Platinum
Status, TUMORRESIDUAL, PRIMARYTHERAPYOUT-
COMESUCCESS, OverallSurvival, ProgressionFreeStatus
and ProgressionFreeSurvival. The dataset is extremely rich
and complex, including also methylation and copy num-
ber variation data (but no proteins). In order to per-
form a fair validation of the above method we only used
mRNA and miRNA data, which could nevertheless recol-
lect important clinical information found in the original
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publication. In the near future we plan to include other
omic layers (methylation/copy number) upon evaluation
of the impact of the diﬀerent data distribution (binomial
and discrete respectively).
We downloaded 489 mRNA and miRNA proﬁles from
HGS-OvCa patients. Among these 489 patients, we
retained only the 287 that have deﬁned information of
the response to platinum treatment (PS, PLATINUM
STATUS). The mRNA dataset is obtained from 3 plat-
forms: Aﬀymetrix Exon 1.0, Agilent 244k Whole Genome
Expression Array and Aﬀymetrix HT-HG-U133A, as
described in Supplementary Methods S6 of [4]. Gene
expression values were rescaled as relative gene expres-
sion values, calculated by subtracting the mean expression
value across samples from the gene estimate and divid-
ing by the standard deviation across patients. To join the
mRNA and miRNA dataset, we calculated the relative
gene expression value for miRNAs in the same way as
mRNAs. The FA+LDA approach let emerge a 13-factor
model (M13) which correlates with important aspects of
the clinical outcomes i.e. PLATINUM STATUS, that is the
response to the platinum-based chemotherapy from the
date of last primary treatment, and VITAL STATUS, or
the living/deceased patients status at follow-up. In par-
ticular, among the 13 factors in M13, F 7 can discrimi-
nate platinum resistance from platinum sensitivity with
accuracy 0.7 and F 8 can discriminate both Living and
Deceased patients signiﬁcantly from all other patients
with accuracy 0.635 and 0.632, respectively.
DAVID functional annotation of the genes identiﬁed
withinM13 revealed several signiﬁcantly represented bio-
logical categories related to HSG ovarian cancer (HSG
Ov-Ca), see Additional ﬁle 2 for the details of the key
molecules and the enriched biological terms. From a gen-
eral point of view functions like Immunity,Antigen presen-
tation and Inﬂammatory response are known to be strictly
connected and to play a fundamental role in the anti-
tumoral immune activity [50,51]. Similarly, physiological
processes like Development, ECM-interaction and Plas-
minogen cascade, normally regulating tissue remodeling,
lead to cancer growth and spreading through metastases,
when altered [52]. We found F 7 and F 8 of particular rel-
evance, as they are able to describe essential and peculiar
aspects of HSG Ov-Ca and they correlate with clini-
cal indexes referring to chemotherapy eﬃcacy such as
resistance/sensitivity to platinum treatment and patients
survival respectively. Speciﬁcally, most of the enriched
pathways characterizing F 7 are related to Development
and Morphogenesis. All the embryonic developmental
processes such as Ectoderm development, Neurogenesis,
Developmental processes, Embryonic skeletal system devel-
opment and morphogenesis, Anterior/posterior pattern
formation share biological terms belonging to the HOX
family of homeobox genes. The precise spatial and
temporal expression of these genes is well acknowledged
to be critical in specifying organ patterning of the repro-
ductive tract during embryogenesis, and in controlling
proliferation, cell migration and DNA repair. Aberrant
activation of such embryonic pathways is implied in the
neoplastic transformation of ovarian cancer tumorigene-
sis [53]. Several studies describe the HOX genes family as
able to inﬂuence HSGOv-Ca subtypes development, their
aggressiveness and the likelihood of metastasis together
with the response to therapy, as such they are biomark-
ers investigated in histopathology [54,55]. In addition to
the HOX gene network an important transcription factor
of embryonic patterning, RUNX3(runt-related transcrip-
tion factor 3), was found to be diﬀerentially expressed
within F 7. RUNX3 has been reported to be overexpressed
in HSG Ov-Ca cells and tissues, upregulating cells pro-
liferation through downstream interference with TGF-β
(transforming growth factor beta) cellular growth inhibi-
tion [56]. It is noteworthy that RUNX3 immuno-staining
in HSG Ov-Ca subtypes samples correlate with clinical-
pathological variables, like overall survival of platinum
treated patients [57]. Hence RUNX3 is a key molecule act-
ing as prognostic factor for HSG Ov-Ca characterization,
since is involved in platinum resistance mechanisms.
Among the miRNAs let-7b and miR-203 in F 7 are note-
worthy (see sheet miRNA lists in Additional ﬁle 2). In
fact, let-7b andmiR-200 families are well acknowledged as
two major microRNA families frequently deregulated in
ovarian cancer and associated with tumor aggressiveness,
tumor invasion and chemoresistance [58,59].
The other relevant factor, F 8 was found to be enriched
for biological processes/pathways such as Immune res-
ponse, Cytokine/chemokine (eg. ILs, CXCLs), Interferon
(IFNs) and Macrophage mediated Immunity, Antigen pre-
sentation and Inﬂammation, based on the functional
analysis on both mRNAs alone and mRNAs and miR-
NAs jointly (see sheet FuncAnnos of mRNA&miRNA,
Additional ﬁle 2). Network representation from STRING
[44] of the genes involved in these biological pro-
cesses/pathways show that the relevant genes highlight
the chemokines family (red oval in Figure 3) and Inter-
feron and cytokines (black oval in Figure 3). These ﬁnd-
ings are of high relevance to HSG Ov-Ca, since immunity
and inﬂammatory cytokines stimulation have been clearly
proven to mainly inﬂuence either the tumor phenotype
or the platinum chemotherapy response [60]. Moreover,
in an elegant large-scale study Yoshihara and colleagues
[61] compared with diﬀerent approaches two sets of data
with the TCGA dataset here analyzed and found the
same set of overrepresented pathways [4]. They estab-
lished a HSG Ov-Ca gene signature consistent with the
TCGA study results, and also found a signiﬁcant corre-
lation between this signature and the platinum treated
patients overall survival. Most of the immune related
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Figure 3 Interactions of genes relevant to the clinical response to Platinum treatment in TCGA. Interactions of the relevant genes in F 8 are
reconstructed using STRING (http://string.embl.de/). Highlighted are the chemokines family (red oval) and the Interferon and cytokines (black oval)
networks. Of remarkable importance is the central role played by CXCL9 (red arrow) in orchestrating the immune and inﬂammatory responses,
which correlate with the platinum therapy eﬃcacy.
signaling pathways these genes belong to, emerge in our
results as well. In particular CXCL9(chemokine (C-X-C
motif ) ligand 9) (highlighted by a red arrow in Figure 3)
is overrepresented in all the biological processes enriched
in F 8. Interestingly, this gene belongs to the molecular
signature they deﬁned as predictive of platinum therapy
response. Additionally they demonstrated that alterations
to the immune system in cancer cells are one of the most
important factors aﬀecting survival of patients with HSG
Ov-Ca and that, in particular, high-risk ovarian cancers
are well characterized by alterations of the immune activ-
ity such as downregulation of the antigen presentation
pathway. In fact, defects in the HLA antigen presentation
machinery are known to decrease recruitment of tumor-
inﬁltrating lymphocytes, leading to poor prognosis in can-
cer patients because of a reduction in antitumor immune
activity [62]. Also, inﬂammation mediated immunity, like
Interferon or other cytokines stimulation, plays a cen-
tral role in response to the therapy since it regulates
the expression of genes in the antigen presentation
signaling [63].
Concerning the miRNA list identiﬁed by F 8 (see sheet
miRNA lists in Additional ﬁle 2) we found miR-30d*,
miR-30b*, miR-155 and let-7f-2* most related to HSGOv-
Ca. miR-30d* is of particular relevance since it has been
signiﬁcantly associated with clinico-pathological indexes,
as platinum treated patients’ disease-free or overall sur-
vival [64]. Among the others, miR-155 is known to be
diﬀerentially expressed in the ovarian cancer tissue and
serum samples [65], whereas miR-30b* and let-7f-2* are
reported to regulate ovarian cancer cells proliferation and
viability [66,67].
Conclusions
We have shown how the use of integrated data and further
processing with FA can enhance the power of the analysis
and give more insight than separate approaches, based on
the same original information. In particular, future work
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is warranted for the integration of additional omic lev-
els, among which the genomic level, for example replacing
our approach to the correlation used in [25] to identify
mutations drivers in cancers, and importantly for the inte-
gration of epigenomic data, which binomial distribution
strongly diﬀers from expression data.
Additional ﬁle
Additional ﬁle 1: Key molecules of melanoma identiﬁed using the FA
based joint and separate analysis for NCI datasets. This .xls ﬁle has two
sheets.The ﬁrst one, named Joint, listed the molecules identiﬁed using the
FA based integrated method (joint analysis). All the molecules are identiﬁed
as a whole, but divided into three groups with the headers mRNA, miRNA
and protein, respectively, in this sheet. The second sheet, named Separate,
includes the molecules identiﬁed using the separate method. Each column
represents one set of molecules resulted from one single omic dataset.
Additional ﬁle 2: Key molecules and functional annotations for the
factors in M13 resulted from TCGA datasets. This .xls ﬁle has four
sheets. The ﬁrst one, namedmRNA lists, listed the mRNAs identiﬁed for
the factors (from F 1 to F 13) in M 13 using the FA based integrated method
(joint analysis), each column includes the key mRNAs for one factor. The
second sheet, namedmiRNA lists is to list the miRNAs for each factor. The
third sheet, named FuncAnnos of mRNAs, are the functional analysis
results of mRNAs, where the mRNAs of each factor are annotated using
DAVID annotation tool to identify the signiﬁcantly enriched terms. The last
sheet, named FuncAnnos of mRNAs&miRNAs, are the functional
annotations of the integration of mRNAs and miRNAs for F 7 and F 8, where
mRNAs and miRNA targets predicted using TargetScan are merged for
DAVID functional analysis.
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